NewsNovo
Omnicell has raised its full-year 2026 non-GAAP earnings per share and EBITDA guidance following strong second-quarter results, though the company warns that rising memory chip costs and a younger installed base could delay the rollout of its new Titan XT platform.
The move highlights a tension between near-term cost discipline and longer-term structural headwinds in the autonomous pharmacy sector.
In the second quarter of 2026, Omnicell reported non-GAAP EBITDA of $67 million, a figure that included a one-time $15 million refund of previously paid International Emergency Economic Powers Act tariffs.
Excluding that refund, the company's EBITDA would have been $52 million, which management noted remained above the midpoint of prior guidance.
Keep reading